Filtered By:
Source: Circulation Journal
Condition: Bleeding
Procedure: Percutaneous Coronary Intervention

This page shows you your search results in order of date.

Order by Relevance | Date

Total 45 results found since Jan 2013.

Polypharmacy and Bleeding Outcomes After Percutaneous Coronary Intervention
CONCLUSIONS: In a real-world population of patients undergoing PCI, approximately 90% were on ≥5 medications. Increasing number of medications was associated with a higher adjusted risk for major bleeding, but not ischemic events.PMID:37722886 | DOI:10.1253/circj.CJ-23-0558
Source: Circulation Journal - September 18, 2023 Category: Cardiology Authors: Ko Yamamoto Takeshi Morimoto Masahiro Natsuaki Hiroki Shiomi Neiko Ozasa Hiroki Sakamoto Yasuaki Takeji Takenori Domei Takeshi Tada Ryoji Taniguchi Takashi Uegaito Miho Yamada Teruki Takeda Hiroshi Eizawa Satoru Suwa Manabu Shirotani Toshihiro Tamura Mori Source Type: research

Dual Antiplatelet Therapy Duration After Multivessel Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention
CONCLUSIONS: The adoption of short DAPT duration was still low in this trial conducted after the release of the STOPDAPT-2 trial results. The 1-year incidence of cardiovascular events was not different between the shorter and longer DAPT groups, suggesting no apparent benefit of prolonged DAPT in reducing cardiovascular events even in patients who undergo multivessel PCI.PMID:37197941 | DOI:10.1253/circj.CJ-23-0141
Source: Circulation Journal - May 17, 2023 Category: Cardiology Authors: Ko Yamamoto Hiroki Shiomi Takeshi Morimoto Akiyoshi Miyazawa Hiroki Watanabe Sunao Nakamura Satoru Suwa Takenori Domei Koh Ono Hiroki Sakamoto Masataka Shigetoshi Ryoji Taniguchi Hideki Okayama Takafumi Yokomatsu Masahiro Muto Ren Kawaguchi Koichi Kishi M Source Type: research

Clopidogrel Use in CYP2C19 Loss-of-Function Carriers With High Bleeding Risk After Percutaneous Coronary Intervention
CONCLUSIONS: Among patients with HBR, clopidogrel use in CYP2C19 LOF carriers was significantly associated with increased ischemic events after PCI.PMID:36792180 | DOI:10.1253/circj.CJ-22-0826
Source: Circulation Journal - February 15, 2023 Category: Cardiology Authors: Yuichi Sawayama Yukinori Tomita Soji Kohyama Yosuke Higo Kenji Kodama Kohei Asada Noriaki Yagi Megumi Fukuyama Atsushi Hayashi Wataru Shioyama Hiroshi Sakai Tomoya Ozawa Tetsuichiro Isono Daiki Hira Takashi Yamamoto Shin-Ya Morita Yoshihisa Nakagawa Source Type: research

Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents  - Results From the HOST-EXAM Trial
CONCLUSIONS: Lower BMI is associated with a higher risk of primary composite outcomes, which is primarily related to the events of all-cause death or major bleeding during chronic maintenance antiplatelet monotherapy after PCI with DES.PMID:36123011 | DOI:10.1253/circj.CJ-22-0344
Source: Circulation Journal - September 19, 2022 Category: Cardiology Authors: Ki-Bum Won Eun-Seok Shin Jeehoon Kang Han-Mo Yang Kyung Woo Park Kyoo-Rok Han Keon-Woong Moon Seok Kyu Oh Ung Kim Moo-Yong Rhee Doo-Il Kim Song-Yi Kim Sung-Yun Lee Jung-Kyu Han Bon-Kwon Koo Hyo-Soo Kim Source Type: research